In summary, these effects indicate that EGCG inhibits VM formation in prostate cancer (PCa) PC-3 cells by targeting the Twist/VE-cadherin/AKT signaling axis (Yeo et al., 2020). This evidence concerns the gene AKT1 and posterior cortical atrophy.